Literature DB >> 30460931

Separate Chinese lines for prostate cancer?

Finn Edler von Eyben1.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 30460931      PMCID: PMC6413554          DOI: 10.4103/aja.aja_71_18

Source DB:  PubMed          Journal:  Asian J Androl        ISSN: 1008-682X            Impact factor:   3.285


× No keyword cloud information.
  7 in total

1.  Androgen deprivation therapy plus docetaxel and estramustine versus androgen deprivation therapy alone for high-risk localised prostate cancer (GETUG 12): a phase 3 randomised controlled trial.

Authors:  Karim Fizazi; Laura Faivre; François Lesaunier; Remy Delva; Gwenaëlle Gravis; Frédéric Rolland; Frank Priou; Jean-Marc Ferrero; Nadine Houede; Loïc Mourey; Christine Theodore; Ivan Krakowski; Jean-François Berdah; Marjorie Baciuchka; Brigitte Laguerre; Aude Fléchon; Alain Ravaud; Isabelle Cojean-Zelek; Stéphane Oudard; Jean-Luc Labourey; Paule Chinet-Charrot; Eric Legouffe; Jean-Léon Lagrange; Claude Linassier; Gaël Deplanque; Philippe Beuzeboc; Jean-Louis Davin; Anne-Laure Martin; Muriel Habibian; Agnès Laplanche; Stéphane Culine
Journal:  Lancet Oncol       Date:  2015-05-28       Impact factor: 41.316

Review 2.  Epidermal growth factor receptor inhibition and non-small cell lung cancer.

Authors:  Finn Edler von Eyben
Journal:  Crit Rev Clin Lab Sci       Date:  2006       Impact factor: 6.250

3.  Surveillance or Metastasis-Directed Therapy for Oligometastatic Prostate Cancer Recurrence: A Prospective, Randomized, Multicenter Phase II Trial.

Authors:  Piet Ost; Dries Reynders; Karel Decaestecker; Valérie Fonteyne; Nicolaas Lumen; Aurélie De Bruycker; Bieke Lambert; Louke Delrue; Renée Bultijnck; Tom Claeys; Els Goetghebeur; Geert Villeirs; Kathia De Man; Filip Ameye; Ignace Billiet; Steven Joniau; Friedl Vanhaverbeke; Gert De Meerleer
Journal:  J Clin Oncol       Date:  2017-12-14       Impact factor: 44.544

4.  Abiraterone plus Prednisone in Metastatic, Castration-Sensitive Prostate Cancer.

Authors:  Karim Fizazi; NamPhuong Tran; Luis Fein; Nobuaki Matsubara; Alfredo Rodriguez-Antolin; Boris Y Alekseev; Mustafa Özgüroğlu; Dingwei Ye; Susan Feyerabend; Andrew Protheroe; Peter De Porre; Thian Kheoh; Youn C Park; Mary B Todd; Kim N Chi
Journal:  N Engl J Med       Date:  2017-06-04       Impact factor: 91.245

5.  Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial.

Authors:  Nicholas D James; Matthew R Sydes; Noel W Clarke; Malcolm D Mason; David P Dearnaley; Melissa R Spears; Alastair W S Ritchie; Christopher C Parker; J Martin Russell; Gerhardt Attard; Johann de Bono; William Cross; Rob J Jones; George Thalmann; Claire Amos; David Matheson; Robin Millman; Mymoona Alzouebi; Sharon Beesley; Alison J Birtle; Susannah Brock; Richard Cathomas; Prabir Chakraborti; Simon Chowdhury; Audrey Cook; Tony Elliott; Joanna Gale; Stephanie Gibbs; John D Graham; John Hetherington; Robert Hughes; Robert Laing; Fiona McKinna; Duncan B McLaren; Joe M O'Sullivan; Omi Parikh; Clive Peedell; Andrew Protheroe; Angus J Robinson; Narayanan Srihari; Rajaguru Srinivasan; John Staffurth; Santhanam Sundar; Shaun Tolan; David Tsang; John Wagstaff; Mahesh K B Parmar
Journal:  Lancet       Date:  2015-12-21       Impact factor: 79.321

6.  Adding abiraterone or docetaxel to long-term hormone therapy for prostate cancer: directly randomised data from the STAMPEDE multi-arm, multi-stage platform protocol.

Authors:  M R Sydes; M R Spears; M D Mason; N W Clarke; D P Dearnaley; J S de Bono; G Attard; S Chowdhury; W Cross; S Gillessen; Z I Malik; R Jones; C C Parker; A W S Ritchie; J M Russell; R Millman; D Matheson; C Amos; C Gilson; A Birtle; S Brock; L Capaldi; P Chakraborti; A Choudhury; L Evans; D Ford; J Gale; S Gibbs; D C Gilbert; R Hughes; D McLaren; J F Lester; A Nikapota; J O'Sullivan; O Parikh; C Peedell; A Protheroe; S M Rudman; R Shaffer; D Sheehan; M Simms; N Srihari; R Strebel; S Sundar; S Tolan; D Tsang; M Varughese; J Wagstaff; M K B Parmar; N D James
Journal:  Ann Oncol       Date:  2018-05-01       Impact factor: 32.976

7.  Clinical activity of abiraterone plus prednisone in docetaxel-naοve and docetaxel-resistant Chinese patients with metastatic castration-resistant prostate cancer.

Authors:  Guo-Wen Lin; Gao-Xiang Li; Bo Dai; Ding-Wei Ye; Yun-Yi Kong; Yue Wang; Yi-Jun Shen
Journal:  Asian J Androl       Date:  2019 Mar-Apr       Impact factor: 3.285

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.